MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Income Overview
Net Income
-$6,356K
EPS
-$5.31
Unit: Thousand (K) dollars
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Income Statement
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Research and development
3,696
3,924
5,700*
4,044
General and administrative
2,747
2,913
2,076*
3,566
Loss from operations
-6,443
-6,837
-7,776*
-7,610
Other income, net
87
140
221*
61
Net loss
-6,356
-6,697
-7,556*
-7,549
Dividend attributable to down round feature of warrants
-
97
-2,866*
1,479
Net loss attributable to common stockholders
-6,356
-6,794
-4,690
-9,028
Basic EPS
-5.31
-6.41
-14.864
-2.23
Diluted EPS
-5.31
-6.41
-14.864
-2.23
Basic Average Shares
1,196,364
1,060,678
315,535*
4,049,046
Diluted Average Shares
1,196,364
1,060,678
315,535*
4,049,046
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Income Statement
Net loss
attributable to common...
-$6,356K
Net loss
-$6,356K
(-2.45%↓ Y/Y)
Other income, net
$87K
(295.45%↑ Y/Y)
Loss from operations
-$6,443K
(-3.49%↓ Y/Y)
Research and development
$3,696K
(11.06%↑ Y/Y)
General and
administrative
$2,747K
(-5.21%↓ Y/Y)
Buy us a coffee
Aptevo Therapeutics Inc. (APVO)
Aptevo Therapeutics Inc. (APVO)